NZ627113A - Substituted pyrimidine compounds and their use as syk inhibitors - Google Patents
Substituted pyrimidine compounds and their use as syk inhibitorsInfo
- Publication number
- NZ627113A NZ627113A NZ627113A NZ62711313A NZ627113A NZ 627113 A NZ627113 A NZ 627113A NZ 627113 A NZ627113 A NZ 627113A NZ 62711313 A NZ62711313 A NZ 62711313A NZ 627113 A NZ627113 A NZ 627113A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compounds
- methyl
- pyrimidine compounds
- substituted pyrimidine
- syk inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- NQRYGQAPAJNGLL-OYRHEFFESA-N 1-[5-[[4-[4-[[(3s,4r)-3,4-dihydroxypyrrolidin-1-yl]methyl]-3-methylpyrazol-1-yl]pyrimidin-2-yl]amino]-1h-indol-3-yl]ethanone Chemical compound C1=C2C(C(=O)C)=CNC2=CC=C1NC(N=1)=NC=CC=1N(N=C1C)C=C1CN1C[C@H](O)[C@H](O)C1 NQRYGQAPAJNGLL-OYRHEFFESA-N 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- AROPBXPDYKPBNJ-UHFFFAOYSA-N cyclopropyl-[5-[[4-[4-[(3-hydroxyazetidin-1-yl)methyl]-3-methylpyrazol-1-yl]pyrimidin-2-yl]amino]indol-1-yl]methanone Chemical compound CC1=NN(C=2N=C(NC=3C=C4C=CN(C4=CC=3)C(=O)C3CC3)N=CC=2)C=C1CN1CC(O)C1 AROPBXPDYKPBNJ-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261588793P | 2012-01-20 | 2012-01-20 | |
| PCT/US2013/022135 WO2013109882A1 (en) | 2012-01-20 | 2013-01-18 | Substituted pyrimidine compounds and their use as syk inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ627113A true NZ627113A (en) | 2016-07-29 |
Family
ID=48799685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ627113A NZ627113A (en) | 2012-01-20 | 2013-01-18 | Substituted pyrimidine compounds and their use as syk inhibitors |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8871778B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2804861B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6062962B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101944914B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN104203943B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2013209586B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2863517C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2668479T3 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ627113A (cg-RX-API-DMAC7.html) |
| PL (1) | PL2804861T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013109882A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201406038B (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ718576A (en) * | 2013-10-21 | 2019-11-29 | Genosco | Substituted pyrimidine compounds and their use as syk inhibitors |
| CN103969445B (zh) * | 2014-05-08 | 2015-09-30 | 中南大学 | 亚铁血红素—二氧化锰复合物的制备及其用于检测人IgG的方法 |
| PT3604294T (pt) * | 2014-10-13 | 2021-07-29 | Yuhan Corp | Compostos e composições para modular atividades da cinase do mutante de egfr |
| ES3042832T3 (en) | 2014-12-29 | 2025-11-24 | Us Health | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof |
| CA3065114A1 (en) * | 2017-06-14 | 2018-12-20 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Syk inhibitor and use method therefor |
| UA125595C2 (uk) * | 2017-07-28 | 2022-04-27 | Юхан Корпорейшн | Проміжні сполуки, корисні для синтезу селективного інгібітора щодо протеїнкінази, і способи їх отримання |
| US12157730B2 (en) | 2019-03-19 | 2024-12-03 | Voronoi Inc. | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component |
| SG11202110376XA (en) | 2019-03-19 | 2021-10-28 | Voronoi Inc | Heteroaryl derivative, method for producing the same, and pharmaceutical composition comprising same as effective component |
| CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
| US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| KR20210152312A (ko) * | 2020-06-08 | 2021-12-15 | 주식회사 종근당 | 카나비노이드 수용체 (cb1 수용체) 길항제로서의 4-(4,5-디하이드로-1h-피라졸-1-닐)피리미딘 화합물 및 이를 포함하는 약제학적 조성물 |
| US20240285621A1 (en) * | 2020-09-23 | 2024-08-29 | Nerviano Medical Sciences S.R.L. | Pyrazolyl-pyrimidine derivatives as kinase inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2194213T3 (es) * | 1996-08-09 | 2003-11-16 | Boehringer Ingelheim Pharma | Beta-carbolinas-4- sustituidas en calidad de inmunomoduladores. |
| AU2004225965A1 (en) * | 2003-03-25 | 2004-10-14 | Vertex Pharmaceuticals Incorporated | Thiazoles useful as inhibitors of protein kinases |
| TW201016676A (en) | 2008-10-03 | 2010-05-01 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
| EP2498607B1 (en) * | 2009-11-13 | 2016-02-17 | Genosco | Kinase inhibitors |
| EP2668177B1 (en) * | 2011-01-28 | 2014-10-22 | Boehringer Ingelheim International GmbH | Substituted pyridinyl-pyrimidines and their use as medicaments |
-
2013
- 2013-01-18 CN CN201380015041.1A patent/CN104203943B/zh active Active
- 2013-01-18 JP JP2014553451A patent/JP6062962B2/ja active Active
- 2013-01-18 CA CA2863517A patent/CA2863517C/en active Active
- 2013-01-18 ES ES13738382.4T patent/ES2668479T3/es active Active
- 2013-01-18 KR KR1020147023266A patent/KR101944914B1/ko active Active
- 2013-01-18 US US13/745,734 patent/US8871778B2/en active Active
- 2013-01-18 NZ NZ627113A patent/NZ627113A/en unknown
- 2013-01-18 AU AU2013209586A patent/AU2013209586B2/en active Active
- 2013-01-18 EP EP13738382.4A patent/EP2804861B1/en active Active
- 2013-01-18 PL PL13738382T patent/PL2804861T3/pl unknown
- 2013-01-18 WO PCT/US2013/022135 patent/WO2013109882A1/en not_active Ceased
-
2014
- 2014-08-18 ZA ZA2014/06038A patent/ZA201406038B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2668479T3 (es) | 2018-05-18 |
| EP2804861A4 (en) | 2015-07-22 |
| CN104203943B (zh) | 2017-12-29 |
| KR101944914B1 (ko) | 2019-02-07 |
| CA2863517A1 (en) | 2013-07-25 |
| US20130274242A1 (en) | 2013-10-17 |
| CA2863517C (en) | 2019-11-05 |
| CN104203943A (zh) | 2014-12-10 |
| EP2804861B1 (en) | 2018-02-28 |
| AU2013209586A1 (en) | 2014-07-24 |
| KR20140135954A (ko) | 2014-11-27 |
| EP2804861A1 (en) | 2014-11-26 |
| AU2013209586B2 (en) | 2017-08-17 |
| JP2015504093A (ja) | 2015-02-05 |
| HK1205106A1 (en) | 2015-12-11 |
| WO2013109882A1 (en) | 2013-07-25 |
| ZA201406038B (en) | 2015-12-23 |
| JP6062962B2 (ja) | 2017-01-18 |
| PL2804861T3 (pl) | 2018-08-31 |
| US8871778B2 (en) | 2014-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ627113A (en) | Substituted pyrimidine compounds and their use as syk inhibitors | |
| EA201390275A1 (ru) | Кристаллический (r)-(e)-2-(4-(2-(5-(1-(3,5-дихлорпиридин-4-ил)этокси)-1h-индазол-3-ил)винил)-1h-пиразол-1-ил)этанол | |
| MY184733A (en) | Pyrimidine fgfr4 inhibitors | |
| MX2015000129A (es) | Derivados de pirimidin pirazolilo. | |
| MX2015002511A (es) | Compuestos de dihidropirimidina y su aplicacion en productos farmaceuticos. | |
| EA201170252A1 (ru) | Амидофеноксиндазолы в качестве ингибиторов c-мет | |
| MY177344A (en) | Compounds and their methods of use | |
| EA201590748A1 (ru) | Противовирусные соединения против rsv | |
| MX2015012431A (es) | Pirrol amida como inhibidores. | |
| EP2883875A4 (en) | N2, N4-BIS (4- (PIPERAZINE-1-YL) PHENYL) PIRIMIDINE-2,4-DIAMINE DERIVATIVE OR PHARMACEUTICALLY UNINTENTIONAL SALT AND COMPOSITION THEREOF AS ACTIVE AGENT FOR THE PREVENTION OR TREATMENT OF CANCER | |
| MX2015009270A (es) | Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk). | |
| PH12015502159A1 (en) | Chemical entities | |
| MX2013010898A (es) | Novedoso derivados de la pirimidina. | |
| MX2013001361A (es) | 4-(1h-indol-3-il) - pirimidina como inhibidores de alk. | |
| HUE046121T2 (hu) | 1-((3-((1-piperazinil)karbonil)fenil)metil)-2,4(1H,3H)-kinazolindion származékok, mint parp gátlók rák kezeléséhez | |
| TN2015000521A1 (en) | Processes of making and crystalline forms of a mdm2 inhibitor | |
| SG10201805392YA (en) | 1,2,4-triazine-6-carboxamide kinase inhibitors | |
| MY167575A (en) | Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases | |
| MX336022B (es) | Activadores de pkm2 bicíclicos. | |
| MX2014013090A (es) | Derivados de pirrolotriazinona. | |
| CU24398B1 (es) | 3-(piperidin,pirrol o azetidin)-indoles sustituidos útiles como inhibidores rorc2 | |
| NZ627560A (en) | Heterocyclic piperazine compounds and methods for their use | |
| PH12016500347A1 (en) | Triazolopyridine compounds, compositions and methods of use thereof | |
| TN2011000428A1 (en) | Uses of nk receptor antagonists | |
| MX2015013414A (es) | N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ERR | Error or correction |
Free format text: THE INVENTOR HAS BEEN CORRECTED TO 3143176, CHOI, JANG-SIK, #105-1304, GYEONGNAM ANUSVILLE APT.,DUJEONG-DONGSEOBUK-GU, CHEONAN-SI331-829, KR; 3143177, HWANG, HAE-JUN, #407-301 TOIGYE JUGONG4 DANGI APT.SEOKSA-DONG, CHUNCHEON200-761, KR; 3143178, LEE, EUNHO, #106-503, HYUNDAI FILLGREEN APT.MABUK-DONG, GIHEUNG-GUYONGIN446-561, KR; 3143179, LEE, JAEKYOO, 19 ELM STREETNORTH ANDOVER, MA 01845, US; 3143180, SONG, HO-JUHN, 141 ARGILLA ROADANDOVER, MA 01810, US; 3143181, KIM, SE WON, #611-702 BYUKSAN APT.,YATAP-DONG, BUNDANG-GUSEONGNAM463-927, KR; 3143182, KIM, JUNG-HO, #707-501 HYOSUNG APT.,IMAEDONG, BUNGDANG-GUSEONGNAM463-737, KR; 3143183, KOH, JONG, SUNG, #404 HANSOL APT.WONJONG 1 DONG 300, OJUNG- Effective date: 20150219 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JAN 2018 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD Effective date: 20161121 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JAN 2019 BY CPA GLOBAL Effective date: 20171214 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JAN 2020 BY CPA GLOBAL Effective date: 20181206 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JAN 2021 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD Effective date: 20191223 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JAN 2022 BY COMPUTER PACKAGES INC Effective date: 20201231 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JAN 2023 BY COMPUTER PACKAGES INC Effective date: 20220117 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JAN 2024 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD Effective date: 20221220 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JAN 2025 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD Effective date: 20231214 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JAN 2026 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD Effective date: 20250118 |